OraSure Technologies: Lack Of Near Term Catalysts (NASDAQ:OSUR)
· seekingalpha.com
OraSure (OSUR) beat Q2 FY26 EPS and revenue as margins improved, but losses widened and key FDA timelines slipped.
I am a specialist in Asian equities after having been a sellside analyst for 13 years. In addition, I have also spent time covering US hardware and semiconducto...